- Danbury Hospital and Norwalk Hospital received approval to join NRG Oncology as primary clinical research sites. This means that patients at Danbury Hospital and Norwalk Hospital now have expanded access to the latest clinical trials for breast cancer, radiation oncology, and gynecologic cancer.
- Through NRG Oncology clinical trials, Danbury Hospital and Norwalk Hospital patients can receive the most promising cancer treatments before they are available to the public.
- The NRG Oncology partnership demonstrates that Danbury Hospital and Norwalk Hospital are highly qualified to participate in innovative cancer research on an international level.
DANBURY, Connecticut, August 28, 2019, Updated September 4, 2020 — Danbury Hospital and Norwalk Hospital received approval to join NRG Oncology as primary clinical research sites. This means that patients at Danbury Hospital and Norwalk Hospital now have expanded access to the latest breast cancer, radiation oncology, and gynecologic cancer clinical trials that are only available to NRG Oncology members.
NRG Oncology is a prestigious, internationally recognized cancer research organization formed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The organization conducts clinical trials and studies to test new cancer treatments and to advance the field of cancer care.
A robust cancer research program
NRG Oncology primary site approval demonstrates that Danbury Hospital and Norwalk Hospital, part of Nuvance Health, are highly qualified to participate in innovative cancer research on an international level. Nuvance Health has a robust team — from clinicians and researchers to administrative staff — and the facilities and resources required to fully support cutting-edge clinical research.
“NRG Oncology is a very important organization so it means a lot to be recognized for our cancer research capabilities,” said Dr. Margo Shoup, senior vice president and system chair of the Nuvance Health Cancer Institute. “As members of NRG Oncology, our clinicians and researchers will be able to engage with oncology leaders from around the world to further expand their knowledge, and then apply advancements to our cancer patients, here at home.”
Dr. Margo Shoup
Dr. Linus Chuang, chair of OB/GYN at Danbury Hospital and Norwalk Hospital is the surgical principle investigators (PI) for NRG Oncology clinical trials. The physician PIs are Dr. Richard Frank, director of clinical cancer research for Nuvance Health Cancer Institute, and a consultant in the gastrointestinal oncology service at Memorial Sloan Kettering Cancer Center (MSK); and, Dr. Wenli Gao, medical oncologist/hematologist at Danbury Hospital.
(Left to Right) Dr. Linus Chuang, Dr. Richard Frank, Dr. Wenli Gao
Improved Access to Clinical Trials for Patients
“Our partnership with NRG Oncology is just another way for us to bring more cancer treatment options to our patients, especially for hard-to-treat cancers,” said Dr. Chuang, who is the American Society of Clinical Oncology (ASCO) International Affairs Committee Chair. “For example, ovarian cancer is the deadliest gynecologic cancer. With NRG Oncology, I hope to bring more ovarian cancer clinical trials to Danbury Hospital and Norwalk Hospital and provide our patients with new treatments that can help improve survival rates.”
Most recently, Danbury Hospital and Norwalk Hospital opened two new gynecologic cancer clinical trials. These clinical trials are giving patients access to new drug options to treat epithelial ovarian, fallopian tube, primary peritoneal, and recurrent ovarian cancers.
Linda Coad, a 78-year old woman from Southbury, Connecticut, was the first patient to enroll in one of these clinical trials at Danbury Hospital, which is testing the effectiveness of neoadjuvant chemotherapy prior to surgery.
Linda Coad was the first patient to enroll in a NRG Oncology ovarian cancer clinical trial at Danbury Hospital
In April 2019, Linda was diagnosed with unresectable advanced stage epithelial ovarian cancer. Due to the advanced stage of the disease, Linda’s Danbury Hospital cancer care team — including Dr. Andikyan and medical oncologist/hematologist Dr. Robert Kloss — determined the most effective treatment for her was chemotherapy first to shrink the tumor.
Dr. Robert Kloss
Linda successfully completed the first round of treatment — the cancerous tumor is shrinking. Her care team will continue to monitor the tumor. If it continues to respond to treatment, she may be able to have debulking surgery to remove the tumor.
“I was perfectly willing to enroll in the clinical trial because I wanted to try a new treatment that could help me now. I also want to help others in the future, which I hope I can do by being part of testing this new treatment,” said Linda. “I’m handling this as an adventure that I’m going to get out of. The way I see it, if the tumor already shrunk, it might shrink more, and then we’ll go from there.”
Linda expected to lose her hair, which is a side effect of the chemotherapy. Besides that and being tired, she said she feels lucky because she’s experienced very few side effects from the treatment.
Learn More about NRG Oncology Clinical Trials
Danbury Hospital and Norwalk Hospital oncologists will let their patients know if they are eligible to enroll in an NRG Oncology clinical trial. People are also encouraged to ask about the clinical trials. For more information, contact Pramila Krumholtz at 203-739-7997.
Vassar Brothers Medical Center, a Nuvance Health hospital in Poughkeepsie, New York, is also an NRG Oncology primary site for clinical research. For more information about clinical trials at Vassar Brothers Medical Center, call 845-483-6825 or email email@example.com.
Amy Forni, Manager, Public Relations
(203) 739 7478 | Amy.Forni@nuvancehealth.org